Japan-based Takeda will create 70 new rolls as well as invest $30.5 million to construct a new regenerative medicine facility at its existing site in Dublin, Ireland.
The new standalone facility will dedicated to manufacturing a novel stem cell therapy. The Dublin site will be the first site to introduce this new technology platform to Takeda’s manufacturing network.
The drugmaker intends for the modular cell therapy operation to be up and running by 2021.
Read the Irish Independent coverage
